Marco Van Eijk

Mr. Marco Van Eijk

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2007 in Diabetes
Verified
Journal Article
Closed access
PDF file
JAJohannes M. Aerts
Johannes M. Aerts
RORoelof Ottenhoff
Roelof Ottenhoff
APAndrew S. Powlson
Andrew S. Powlson
AGAldo Grefhorst
Aldo Grefhorst
MEMarco Van Eijk
Marco Van Eijk
HOHermen S. Overkleeft
Hermen S. Overkleeft
A growing body of evidence implicates ceramide and/or its glycosphingolipid metabolites in the pathogenesis of insulin resistance. We have developed a highly specific small molecule inhibitor of glucosylceramide synthase, an enzyme that catalyzes a necessary step in the conversion of ceramide to glycosphingolipids. In cultured 3T3-L1 adipocytes, the iminosugar derivative N-(5′-adamantane-1′-yl-methoxy)-pentyl-1-deoxynojirimycin (AMP-DNM) counteracted tumor necrosis factor-α–induced abnormalities in glycosphingolipid concentrations and concomitantly reversed abnormalities in insulin signal transduction. When administered to mice and rats, AMP-DNM significantly reduced glycosphingolipid but not ceramide concentrations in various tissues. Treatment of ob/ob mice with AMP-DNM normalized their elevated tissue glucosylceramide levels, markedly lowered circulating glucose levels, improved oral glucose tolerance, reduced A1C, and improved insulin sensitivity in muscle and liver. Similarly beneficial metabolic effects were seen in high fat–fed mice and ZDF rats. These findings provide further evidence that glycosphingolipid metabolites of ceramide may be involved in mediating the link between obesity and insulin resistance and that interference with glycosphingolipid biosynthesis might present a novel approach to the therapy of states of impaired insulin action such as type 2 diabetes.

7 October 2005 in International Immunology
Verified
Journal Article
Open access
PDF file
MEMarco Van Eijk
Marco Van Eijk
CRCindy P. A. A. van Roomen
Cindy P. A. A. van Roomen
HRHerma Renkema
Herma Renkema
ABAnton P. Bussink
Anton P. Bussink
LALaura Andrews
Laura Andrews
JAJohannes M. Aerts
Johannes M. Aerts
Man has been found to produce highly conserved chitinases. The most prominent is the phagocyte-derived chitotriosidase, the plasma levels of which are markedly elevated in some pathological conditions. Here, we report that both polymorphonuclear neutrophils (PMNs) and macrophages (mϕ) are a source of chitotriosidase. The enzyme is located in specific granules of human PMNs and secreted following stimulation with granulocyte macrophage colony-stimulating factor (GM-CSF). In addition, GM-CSF induces expression of chitotriosidase in mϕ that constitutively secrete the enzyme and partly accumulate it in their lysosomes. Studies with recombinant human chitotriosidase revealed that the enzyme targets chitin-containing fungi. These findings are consistent with earlier observations concerning anti-fungal activity of homologous plant chitinases and beneficial effects of GM-CSF administration in individuals suffering from invasive fungal infections. In conclusion, chitotriosidase should be viewed as a component of the innate immunity that may play a role in defence against chitin-containing pathogens and the expression and release of which by human phagocytes is highly regulated.

5 June 2017 in Nature Chemical Biology
Verified
Journal Article
Closed access
LWLiang Wu
Liang Wu
JJJianbing Jiang
Jianbing Jiang
YJYi Jin
Yi Jin
WKWouter W. Kallemeijin
Wouter W. Kallemeijin
CKChi-Lin Kuo
Chi-Lin Kuo
GDGideon J Davies
Gideon J Davies

23 March 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MEMarco Van Eijk
Marco Van Eijk
JAJan Aten
Jan Aten
NBNora Bijl
Nora Bijl
RORoelof Ottenhoff
Roelof Ottenhoff
CRCindy P. A. A. van Roomen
Cindy P. A. A. van Roomen
JAJohannes M. Aerts
Johannes M. Aerts
Adipose tissue is a critical mediator in obesity-induced insulin resistance. Previously we have demonstrated that pharmacological lowering of glycosphingolipids and subsequently GM3 by using the iminosugar AMP-DNM, strikingly improves glycemic control. Here we studied the effects of AMP-DNM on adipose tissue function and inflammation in detail to provide an explanation for the observed improved glucose homeostasis. Leptin-deficient obese (LepOb) mice were fed AMP-DNM and its effects on insulin signalling, adipogenesis and inflammation were monitored in fat tissue. We show that reduction of glycosphingolipid biosynthesis in adipose tissue of LepOb mice restores insulin signalling in isolated ex vivo insulin-stimulated adipocytes. We observed improved adipogenesis as the number of larger adipocytes was reduced and expression of genes like peroxisome proliferator-activated receptor (PPAR) γ, insulin responsive glucose transporter (GLUT)-4 and adipsin increased. In addition, we found that adiponectin gene expression and protein were increased by AMP-DNM. As a consequence of this improved function of fat tissue we observed less inflammation, which was characterized by reduced numbers of adipose tissue macrophages (crown-like structures) and reduced levels of the macrophage chemo attractants monocyte-chemoattractant protein-1 (Mcp-1/Ccl2) and osteopontin (OPN). In conclusion, pharmacological lowering of glycosphingolipids by inhibition of glucosylceramide biosynthesis improves adipocyte function and as a consequence reduces inflammation in adipose tissue of obese animals.

14 December 2009 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TWTom Wennekes
Tom Wennekes
AMAlfred J. Meijer
Alfred J. Meijer
AGAlbert K. Groen
Albert K. Groen
RBRolf Boot
Rolf Boot
JGJohanna E. Groener
Johanna E. Groener
JAJohannes M. Aerts
Johannes M. Aerts

1 January 2015 in Kidney International
Verified
Journal Article
Closed access
MDMark C. Dessing
Mark C. Dessing
Alessandra TammaroAlessandra Tammaro
Alessandra Tammaro
WPWilco P. Pulskens
Wilco P. Pulskens
GTGwendoline J. Teske
Gwendoline J. Teske
LBLoes M. Butter
Loes M. Butter
JLJaklien C. Leemans
Jaklien C. Leemans